Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years
Portfolio Pulse from
Tonix Pharmaceuticals (TNXP) has successfully had its New Drug Application (NDA) for TNX-102 SL accepted by the FDA for treating fibromyalgia. This could potentially represent the first new fibromyalgia drug in 15 years, marking a significant milestone for the company's pharmaceutical development efforts.
March 26, 2025 | 6:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FDA acceptance of TNX-102 SL NDA represents a critical regulatory milestone that could open significant market opportunities in fibromyalgia treatment.
FDA acceptance of NDA indicates strong potential for drug approval, which could substantially increase company's market value and stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100